Official ESCRS | European Society of Cataract & Refractive Surgeons
Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance

Take a look inside the London 2014 Congress


Then register to join us
in Barcelona!

Clinical outcome and learnings for optimising outcomes with the Supracor LASIK treatment for myopic presbyopes

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Corneal and Scleral Treatment

Session Date/Time: Wednesday 09/09/2015 | 08:00-09:30

Paper Time: 08:06

Venue: Room 13

First Author: : K.Liesto FINLAND

Co Author(s): :    J. Rinta-Rahko                    

Abstract Details


The Supracor LASIK presbyopic treatment has been indicated for use in hyperopic patients for a number of years. More recently, the procedure received CE Mark approval for use in myopes. A clinical evaluation on the outcomes using the supracor lasik algorithm in myopic presbyopic patients was conducted and clinical pearls for optimising outcomes developed with growing experience.


Mehilainen Group, Helsinki, Finland


Single centre evaluation on 19 myopic presbyopes selected to undergo the Supracor LASIK (Bausch + Lomb Technolas). All flap procedures were performed with a Femto-lasik procedure (Visumax-femto) and ablation with the excimer laser (Technolas 217z100). The myopic patients underwent a monolateral regular supracor treatment in the non-dominant eye and a PTA treatment in the dominant eye. Target refraction was -0.5D.


Up to 6 months follow-up data is available. Mean patient age was 47.8 years. Pre-operative spherical equivalent (SE), sphere and cylinder were -3.00D, -2.72D and -0.56D, respectively. At 6 months post-op, SE, sphere and cylinder were -0.36D, -0.32D and – 0.09D. All patients achieved monocular BCDVA of 0.8 decimal and 81% had 1.0 decimal. For monocular UDVA, 73% had 0.8 decimal. 80% patients achieved UNVA of J2 or better. Further follow up data will be presented.


Ongoing experience with the Supracor LASIK presbyopic treatment finds it is safe, effective and predictable for clinical use in myopic patients, thus widening the scale of patients suitable for a LASIK-based treatment for presbyopia. Early outcomes when a combining PTA in the dominant eye with Supracor in non-dominant eyes indicate it is a good balance for providing good vision whilst preserving distance vision. Further data is required to confirm these findings. Careful patient selection and management is required to optimise outcomes and patient satisfaction.

Financial Interest:

One of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented

Back to previous